



Xenome Completes A\$8.0 million Financing Funds to Advance Proof of Concept Clinical Studies

BRISBANE, Australia, 21 December 2011: Biopharmaceutical company Xenome Limited ("Xenome") announced it has completed a financing of A\$8 million. Participants in the financing comprised existing investors Queensland BioCapital Fund and GBS Venture Partners.

Xenome is developing Xen2174, a new therapeutic being developed for the management of moderate to severe pain. Xen2174 is a proprietary 13-amino acid synthetic peptide, which has shown promise as a non-opiate pain therapeutic when administered intrathecally.

The current financing is intended to support the ongoing development of Xen2174, in particular a phase II placebo controlled multi-center clinical trial of Xen2174 in a post bunionectomy surgical patient population. This trial is intended to demonstrate Xen2174's potential to provide improved postoperative pain relief for an extended period following a single intrathecal administration immediately prior to surgery.

About Xenome:

Xenome is a biopharmaceutical company focused on the discovery and development of peptide-based therapeutics. The Company's lead molecule, Xen2174, is a novel conopeptide analogue being developed for the management of moderate to severe pain. Xen2174 is a highly selective and non-competitive inhibitor of norepinephrine transporter (NET), a validated target for the management of pain.

Contact information:

Company:

Michael Aldridge

Executive Director

Xenome Limited

Mobile: +1 650 452 4684

E: michael.aldridge@xenome.com

Intentionally Blank